glimepiride glp 1 Clinical Focus on GLP-1 Agonists in Type 2 Diabetes Mellitus GLP-1 programs the neurovascular landscape:

Understanding how these drugs work and consulting your healthcare provider about timing and dosing remains essential for safe,

The Australia GLP-1 receptor agonist market size was valued at USD 570.49 million in 2025 and is expected to hit around USD 2,117.46 million by 2035, growing at a CAGR of 14.01% from 2026 to 2035.

Leading diabetes players Novo Nordisk and Lilly are set to dominate the race for the obesity opportunity

The Medicines and Healthcare products Regulatory Agency (MHRA) has warned healthcare professionals to be aware of the potential risk of pulmonary aspiration in patients using glucagon-like peptide-1 (GLP-1) or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (GLP-1 RAs), who undergo surgery or procedures with general anaesthesia or deep sedation